Nearly 2/3 of all HF hospitalizations occur because our patients' oral diuretics fail to decongest them adequately due to diuretic resistance. As a result, they require admission for IV diuretics as their only additional therapy. Intranasal bumetanide is a new formulation of a commonly-used loop diuretic (Bumex) that has been developed to be used through a nasal inhaler much like Narcan, the triptans and other agents. The intranasal route works rapidly and avoids first-pass hepatic metabolism. Recent PK/PD data in normal subjects has shown equivalent pharmacodynamics (urine and sodium output) when compared to IV and oral dosing. Studies now pending to see if intranasal bumetanide will help overcome diuretic resistance in our congested HF patients and keep them out of the hospital. #intranasalbumetanide #decongestathome Corstasis Therapeutics
CEO non-profit Baim / PERFUSE Research Institute, Harvard Professor, Cardiologist BIDMC, Founder & Chairman WikiDoc.org
Bumetanide nasal spray safe, has equivalent pharmacodynamic efficacy (urine/sodium output) compared to IV and PO bumetanide administration. View slides here: https://lnkd.in/eJZYfzfj
